An Open Label, Drug-drug Interaction Study to Assess the Effect of Multiple Doses of Gemfibrozil on the Single Dose Pharmacokinetics of ASP3652 and to Assess the Effect of Multiple Doses of ASP3652 on the Single Dose Pharmacokinetics of Repaglinide

Trial Profile

An Open Label, Drug-drug Interaction Study to Assess the Effect of Multiple Doses of Gemfibrozil on the Single Dose Pharmacokinetics of ASP3652 and to Assess the Effect of Multiple Doses of ASP3652 on the Single Dose Pharmacokinetics of Repaglinide

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Jun 2014

At a glance

  • Drugs ASP 3652 (Primary) ; Gemfibrozil (Primary) ; Repaglinide (Primary)
  • Indications Hyperlipidaemia; Interstitial cystitis; Prostatitis; Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Astellas Pharma Europe Ltd
  • Most Recent Events

    • 26 Feb 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top